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Abstract
An important cause of bacterial resistance to aminoglycoside antibiotics is the enzymatic acetylation of their amino groups
by acetyltransferases, which abolishes their binding to and inhibition of the bacterial ribosome. Enhanced intracellular
survival (Eis) protein from Mycobacterium tuberculosis (Mt) is one of such acetyltransferases, whose upregulation was
recently established as a cause of resistance to aminoglycosides in clinical cases of drug-resistant tuberculosis. The
mechanism of aminoglycoside acetylation by MtEis is not completely understood. A systematic analysis of steady-state
kinetics of acetylation of kanamycin A and neomycin B by Eis as a function of concentrations of these aminoglycosides and
the acetyl donor, acetyl coenzyme A, reveals that MtEis employs a random-sequential bisubstrate mechanism of acetylation
and yields the values of the kinetic parameters of this mechanism. The implications of these mechanistic properties for the
design of inhibitors of Eis and other aminoglycoside acetyltransferases are discussed.
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Introduction
The emergence and spread of multidrug-resistant bacteria is a
worldwide problem that requires deep understanding of the
resistance mechanisms to develop novel rational approaches to
antibacterial therapy. There are several mechanisms of bacterial
drug resistance and one is chemical drug modification by the
pathogen. Mycobacterium tuberculosis (Mt) is a notoriously pervasive
infectious bacterium, whose multidrug-resistant strains are steadily
spreading globally. A large fraction of clinical isolates of M.
tuberculosis that are resistant to a second-line anti-tuberculosis
antibiotic, the aminoglycoside (AG) kanamycin A (KAN), do not
bear any ribosomal mutations that weaken inhibition by AGs
[1,2]. Instead, these strains harbor upregulating mutations in the
promoter of the eis (enhanced intracellular survival) gene encoding
an AG acetyltransferase, Eis [1]. KAN acetylated by MtEis does
not have any antibacterial activity [1,3]. MtEis, unlike other AG
acetyltransferases, is capable of acetylating AGs efficiently at
several amino groups, thus displaying an unusual regioversatility
and strong AG inactivation properties [4]. Several AGs that are
used in clinic and the second-line anti-tuberculosis drug capreo-
mycin are rendered inactive by the acetylating activity of MtEis
[5]. Moreover, some acetylation positions are unique to this
enzyme, since they are not modified by other acetyltransferases
[3]. Because Eis homologs are found in many other bacteria in
addition to mycobacteria [6,7], they pose a formidable challenge
as an AG resistance factor. Moreover, because of the broad
substrate versatility of Eis, a traditional approach to overcoming
Eis-based resistance by designing a novel AG antibiotic that
cannot be acetylated by Eis, is not likely to succeed.
The kinetic mechanism of AG acetylation by MtEis remains
incompletely understood. Similarly to other acetyltransferases,
MtEis uses acetyl coenzyme A (AcCoA) as the acetyl group donor
and, therefore, MtEis is a bisubstrate enzyme. The AG substrate
and the AcCoA can bind the enzyme either in a strict order or
randomly to form the preacetylation ternary complex. While some
AG acetyltransferases were demonstrated to obey a random
sequential mechanism [8–11], others employ an ordered sequen-
tial mechanism where AcCoA needs to bind the enzyme first
followed by the AG [12–14], and some of the enzymes follow one
or the other mechanism depending on the AG scaffold [15]. A
mechanism where the AG must bind the enzyme first has not been
reported yet, to our knowledge. We recently demonstrated that a
homolog of MtEis from Mycobacterium smegmatis obeys the random
sequential mechanism of KAN acetylation [6]. Here, we report a
systematic kinetic analysis of the clinically relevant enzyme, MtEis,
with two AGs, KAN and neomycin B (NEO). KAN, a member of
the 4,6-disubstituted 2-deoxystreptamine family of AGs, was
selected because it is a second-line drug used in treatment of
extensively drug-resistant tuberculosis. NEO was chosen as a
representative of another major family of AGs, the 4,5-disubsti-
tuted 2-deoxystreptamine, in order to test if the mechanism of
multiacetylation by MtEis is dependent on the molecular scaffold
of the drug.
Materials and Methods
Materials
MtEis was expressed and purified as previously reported [4].
KAN, NEO, and AcCoA were purchased from Sigma-Aldrich (St.
Louis, MO, USA) and used without any further purification.
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Steady-state acetyltransferase assays
Reactions were carried out in Tris buffer (50 mM, pH 8.0)
using varying concentrations of KAN or NEO (0, 20, 50, 100, 250,
500, 1000, and 2000 mM) at several concentrations of AcCoA (25,
50, 100, 200, 300, and 500 mM) using constant concentrations of
Eis (0.25 mM) and 5,59-dithiobis-(2-nitrobenzoic acid) (DTNB,
2 mM). Reactions were monitored using a SpectraMax M5
multimode plate reader by taking absorbance measurements at
412 nm every 15 s for 15 min. Initial rates were calculated using
the first 1.5 min of the reaction.
Analysis of the bisubstrate kinetics of AG acetylation by
MtEis
A random sequential rapid equilibrium bisubstrate mechanism
is given by the following kinetic scheme [6]:
EzAGzAcCoA/? E.AGzAcCoA/? E.AG.AcCoA
EzAGzAcCoA/? E.AcCoAzAG/? E.AG.AcCoA
E.AG.AcCoA?AGAczCoAzE,
ð1Þ
where E designates the enzyme, AG and AG-Ac is the
aminoglycoside and its acetylated form, respectively, and AcCoA
and CoA are acetyl coenzyme A and coenzyme A, respectively.
Then, under pseudo-first order conditions (large excess of the two
substrates over the enzyme), the apparent Michaelis-Menten
parameters in terms of the microscopic mechanism parameters
are:
kcat,AG~
kcat½AcCoA
Kd,AcCoA(E.AG)z½AcCoA ð2Þ
Km,AG~Kd,AG(E.AcCoA)
Kd,AcCoA(E)z½AcCoA
Kd,AcCoA(E.AG)z½AcCoA
 
ð3Þ
kcat,AcCoA~
kcat½AG
Kd,AG(E.AcCoA)z½AG ð4Þ
Km,AcCoA~Kd,AcCoA(E.AG)
Kd,AG(E)z½AG
Kd,AG(E.AcCoA)z½AG
 
ð5Þ
Here, the subscript ‘‘AG’’ for Kcat and Km means that this constant
is obtained from the dependence of the steady-state rate on the
concentration of AG measured at a fixed concentration of AcCoA.
The analogous nomenclature is used for AcCoA. For the subscript
nomenclature of equilibrium binding constants Kd, for example,
Kd,AG(ENAcCoA) is the equilibrium constant for binding of AG to
ENAcCoA complex, etc; kcat is the microscopic rate constant of the
acetylation step (last equation in scheme (1)).
In the scheme for the ordered mechanism in which AcCoA
must bind the enzyme first, the above parameters have the
following functional form:
kcat,AG~kcat ð6Þ
Km,AG~Kd,AG 1z
Kd,AcCoA
½AcCoA
 
ð7Þ
kcat,AcCoA~
kcat½AG
Kd,AGz½AG ð8Þ
Km,AcCoA~
Kd,AcCoAKd,AG
Kd,AGz½AG ð9Þ
The ordered mechanism is ruled out by the observed kinetics, as
described in the Results and Discussion section. Because the
kinetics were measured in sets of experiments at different fixed
concentrations of AcCoA for each concentration of AcCoA
varying the concentration of AG, a statistically rigorous way of
determining the microscopic mechanism constants Kd and kcat
from the data is to determine the apparent Michaelis-Menten
constants kcat,AG and Km,AG first. The next step is to fit dependence
of kcat,AG on [AcCoA] described by eq. (2) to the respective
observed values, to obtain kcat and Kd,AcCoA(ENAG). These values are
obtained for each AG independently. Finally, because Kd,AcCoA(E)
is AG-independent, its value is determined by a nonlinear
regression data fitting of eq. (3) to the observed Km,AG dependence
on [AcCoA] for KAN and NEO together. In the same fitting
procedure two independent values Kd,AG(ENAcCoA) for KAN and
NEO are obtained. This analysis was performed by nonlinear
regression with SigmaPlot 11.0 (SysStat). We have observed a
preparation-dependent activity of Eis, varying within a 4-fold
range. For this reason, all experiments in this study were
performed with the same preparation of MtEis. The differences
in fraction of active MtEis translate in corresponding differences in
values of kcat reported in this and other studies. Values of Km and
Kd as well as the relative differences in kcat values for different AGs
are not affected by this variability.
Results and Discussion
Steady-state kinetic measurements of KAN and NEO
acetylation by MtEis
In order to distinguish among the two ordered sequential
mechanisms and a random sequential mechanism of binding of
the AG and the AcCoA to MtEis to form a ternary acetylation
complex, we performed a series of steady-state acetylation kinetic
assays as a function of two independent variables, the concentra-
tions of AG and AcCoA, both in large excess of the enzyme. These
experiments were carried out with two AGs, KAN and NEO. For
both KAN and NEO, the steady-state rate of acetylation by MtEis
followed a hyperbolic dependence when plotted as a function of
concentration of AG at a fixed concentration of AcCoA
(Figures 1A and 2A for KAN and NEO, respectively) or as a
function of concentration of AcCoA at a fixed concentration of
AG (Figures 1B and 2B for KAN and NEO, respectively). Each of
such hyperbolic dependences for KAN and NEO, where the
concentration of AG is an independent variable (Figures 1A and
2A, respectively) yields apparent Michaelis-Menten constants,
Km,AG and kcat,AG. Dependence of these constants on the
concentration of AcCoA is also hyperbolic within the experimental
uncertainty (Figures 1C, 1D for KAN and Figures 2C, 2D for
NEO). We observe that Km,AG increases with increasing concen-
tration of AcCoA (Figures 1D and 2D) for both KAN and NEO;
this is possible only for a random sequential mechanism (scheme
(1), eq. (3)), where Kd,AcCoA(E),Kd,AcCoA(ENAG), i.e., AcCoA has a
higher affinity towards free enzyme than towards AG bound
enzyme. In other words, binding of AcCoA and AG is anti-
cooperative. A similar observation was made recently about KAN
Kinetics of Acetyltransferase Eis
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acetylation by the Eis homolog from M. smegmatis based on a more
limited set of experiments [6].
The rapid equilibrium mechanism of acetylation by MtEis
makes physical sense, when one considers the ability of MtEis to
efficiently acetylate AGs at multiple amino groups. This random
sequential mechanism would allow an AG bound to MtEis to
simply change its orientation in the active site after one
acetylation, independently of dissociation of the CoA product
and binding of another AcCoA for subsequent acetylation of the
same AG. In contrast, if, for example, AG binding strictly followed
AcCoA binding, the AG would need to dissociate after each
acetylation event in order to rebind the same or another enzyme
bound to AcCoA.
The quantitative analysis of these kinetic data in terms of the
random sequential mechanism yields microscopic Michaelis-
Menten parameter values for KAN and NEO. We obtain similar
values of kcat for KAN and NEO (kcat = 0.6860.15 s
21 and
0.8660.16 s21) (Figure 1A, 1C and Figure 2A, 2C) and a
somewhat higher affinity of AcCoA to the KAN bound enzyme
than to the NEO bound enzyme (Kd,AcCoA(AGNE) = 45637 mM and
111662 mM, for KAN and NEO, respectively). On the other
hand, NEO binds the AcCoA bound enzyme with an approx-
imately 3-fold higher affinity than KAN (Figures 1D and 2D); the
values of the equilibrium binding constants obtained from the
simultaneous fit of the KAN and NEO acetylation data (see
Materials and Methods) are Kd,AG(AcCoANE) = 439652 mM and
135653 mM for KAN and NEO, respectively. This analysis also
yields the equilibrium constant for binding of AcCoA to MtEis,
Kd,AcCoA(E) = 18614 mM. It is to note that this value of Kd,AcCoA(E)
is about 4-fold lower than that for AcCoA binding to Eis from M.
smegmatis reported recently [6] and not equal to it, as it was
assumed. Because the four equilibria in scheme (1) form a
thermodynamic cycle, any three Kd values yield the fourth one, in
this case the equilibrium constant for binding of AG to free enzyme,
Kd,AG(E) =Kd,AcCoA(E)Kd,AG(AcCoANE)/Kd,AcCoA(AGNE) = 1766144 mM
and 22617 mM for KAN and NEO, respectively. These results
demonstrate quantitatively the anti-cooperativity of AcCoA and AG
binding, as discussed above based on qualitative grounds. A
different, four-ring structure of NEO from the three-ring structure
of KAN may explain stronger binding of NEO to MtEis. In
addition, NEO is tri-acetylated byMtEis while KAN is di-acetylated
[3,4], indicating that NEO binds MtEis in more orientations than
KAN does, which may explain the higher affinity of NEO to MtEis.
Relationship to other AG acetyltransferases and
considerations for the design of MtEis inhibitors
The random sequential mechanism is more common among
characterized AG acetyltransferases than the ordered sequential
mechanism where AcCoA binds the enzyme first. The ability of
either AG or AcCoA to bind the free enzyme raises a possibility
that bisubstrate compounds combining the chemical features of
both substrates can be developed as MtEis inhibitors, which would
be more potent than respective substrate analog inhibitors
individually or as a combination. The 4,5-disubstituted 2-
deoxystreptamine four-ring scaffold of NEO appears to be more
promising than the 4,6-disubstituted 2-deoxystreptamine three-
ring scaffold of KAN for such design, based on the stronger affinity
of NEO to MtEis. Bisubstrate inhibitors of GCN5-related N-
acetyltransferases have been reported [16–21]. Blanchard and
colleagues developed and elegantly applied analysis of the
inhibition kinetics by such inhibitors to the dissection of the
kinetic mechanism, an alternative to the analysis presented in this
Figure 1. Steady-state kinetics of KAN acetylation by MtEis and their analysis. A. Representative dependences of the steady-state rate of
acetylation of KAN on the concentration of KAN at different concentrations of AcCoA, as specified. B. Representative dependences of the steady-state
rate of acetylation of KAN on the concentration of AcCoA at different concentrations of KAN, as specified. C. Dependence of the apparent rate
constant (kcat,AG), as obtained from data shown in panel A, on the concentration of AcCoA. D. Dependence of the apparent Km,AG, as obtained from
data shown in panel A, on the concentration of AcCoA. The theoretical curve in D is the best simultaneous fit of eq. (3) to these values and those for
acetylation of NEO as described in the text.
doi:10.1371/journal.pone.0092370.g001
Kinetics of Acetyltransferase Eis
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study [22]. Consistent with the thermodynamic argument made
above, a bisubstrate inhibitor of the E. coli AAC(3)-IV acetyltrans-
ferase, which obeys the random sequential mechanism, is
extremely strong, and its intrinsic Ki could be obtained only by
extrapolation [22]. These examples demonstrate the power of
bisubstrate inhibitors as chemical probes. Even though therapeu-
tically useful bisubstrate inhibitors of acetyltransferase targets have
not emerged yet, examples of bisubstrate inhibitors of other
enzymes that are used in clinic exist [22]. Development of a potent
bisubstrate inhibitor of MtEis as a selective probe or a
pharmaceutical lead, based on its unique structure and catalytic
properties, is an attractive direction for future studies. Studies
focusing on the development of such bisubstrate inhibitors of
MtEis are currently underway in our laboratories.
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